Protagonist partners IBD compound PTG200 with Janssen Biotech; deal expanded
In a potential $990mm deal, Protagonist Therapeutics Inc. is licensing Janssen Biotech Inc. exclusive global rights to develop, manufacture, and commercialize its PTG200 and related interleukin-23 receptor antagonists for all indications including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.
- Large Molecule
- Includes Royalty or Profit Split Information
- Manufacturing or Supply
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.